166 related articles for article (PubMed ID: 38538564)
1. Melanoma-associated fibroblasts in tumor-promotion flammation and antitumor immunity: novel mechanisms and potential immunotherapeutic strategies.
Zhou Q; Jin X; Zhao Y; Wang Y; Tao M; Cao Y; Yin X
Hum Mol Genet; 2024 Mar; ():. PubMed ID: 38538564
[TBL] [Abstract][Full Text] [Related]
2. Targeting Melanoma-Associated Fibroblasts (MAFs) with Activated γδ (Vδ2) T Cells: An In Vitro Cytotoxicity Model.
Hajdara A; Çakır U; Érsek B; Silló P; Széky B; Barna G; Faqi S; Gyöngy M; Kárpáti S; Németh K; Mayer B
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629075
[TBL] [Abstract][Full Text] [Related]
3. Converting melanoma-associated fibroblasts into a tumor-suppressive phenotype by increasing intracellular Notch1 pathway activity.
Shao H; Moller M; Cai L; Prokupets R; Yang C; Costa C; Yu K; Le N; Liu ZJ
PLoS One; 2021; 16(3):e0248260. PubMed ID: 33705467
[TBL] [Abstract][Full Text] [Related]
4. Metastasis-associated fibroblasts: an emerging target for metastatic cancer.
Wang Z; Liu J; Huang H; Ye M; Li X; Wu R; Liu H; Song Y
Biomark Res; 2021 Jun; 9(1):47. PubMed ID: 34112258
[TBL] [Abstract][Full Text] [Related]
5. The nexus of natural killer cells and melanoma tumor microenvironment: crosstalk, chemotherapeutic potential, and innovative NK cell-based therapeutic strategies.
Rahimi A; Malakoutikhah Z; Rahimmanesh I; Ferns GA; Nedaeinia R; Ishaghi SMM; Dana N; Haghjooy Javanmard S
Cancer Cell Int; 2023 Dec; 23(1):312. PubMed ID: 38057843
[TBL] [Abstract][Full Text] [Related]
6. Insights into Melanoma Fibroblast Populations and Therapeutic Strategy Perspectives: Friends or Foes?
Avagliano A; Arcucci A
Curr Med Chem; 2022; 29(40):6159-6168. PubMed ID: 35726413
[TBL] [Abstract][Full Text] [Related]
7. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
8. A Framework of Major Tumor-Promoting Signal Transduction Pathways Implicated in Melanoma-Fibroblast Dialogue.
Bellei B; Migliano E; Picardo M
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33212834
[TBL] [Abstract][Full Text] [Related]
9. From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review.
Regmi M; Wang Y; Liu W; Dai Y; Liu S; Ma K; Lin G; Yang J; Liu H; Wu J; Yang C
J Exp Clin Cancer Res; 2024 Feb; 43(1):47. PubMed ID: 38342925
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal-Stromal Cell-like Melanoma-Associated Fibroblasts Increase IL-10 Production by Macrophages in a Cyclooxygenase/Indoleamine 2,3-Dioxygenase-Dependent Manner.
Çakır U; Hajdara A; Széky B; Mayer B; Kárpáti S; Mezey É; Silló P; Szakács G; Füredi A; Pós Z; Érsek B; Sárdy M; Németh K
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944793
[TBL] [Abstract][Full Text] [Related]
11. Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma.
Zhou L; Yang K; Andl T; Wickett RR; Zhang Y
J Cancer; 2015; 6(8):717-26. PubMed ID: 26185533
[TBL] [Abstract][Full Text] [Related]
12. Transcription factors in fibroblast plasticity and CAF heterogeneity.
Melchionna R; Trono P; Di Carlo A; Di Modugno F; Nisticò P
J Exp Clin Cancer Res; 2023 Dec; 42(1):347. PubMed ID: 38124183
[TBL] [Abstract][Full Text] [Related]
13. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment.
Marzagalli M; Ebelt ND; Manuel ER
Semin Cancer Biol; 2019 Dec; 59():236-250. PubMed ID: 31404607
[TBL] [Abstract][Full Text] [Related]
14. Lactic acid in macrophage polarization: A factor in carcinogenesis and a promising target for cancer therapy.
Ajam-Hosseini M; Heydari R; Rasouli M; Akhoondi F; Asadi Hanjani N; Bekeschus S; Doroudian M
Biochem Pharmacol; 2024 Apr; 222():116098. PubMed ID: 38431231
[TBL] [Abstract][Full Text] [Related]
15. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
17. Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma.
Hargadon KM
Front Immunol; 2017; 8():1594. PubMed ID: 29209327
[TBL] [Abstract][Full Text] [Related]
18. Microenvironment‑driven resistance to B‑Raf inhibition in a melanoma patient is accompanied by broad changes of gene methylation and expression in distal fibroblasts.
Kodet O; Dvořánková B; Bendlová B; Sýkorová V; Krajsová I; Štork J; Kučera J; Szabo P; Strnad H; Kolář M; Vlček Č; Smetana K; Lacina L
Int J Mol Med; 2018 May; 41(5):2687-2703. PubMed ID: 29393387
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
20. Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy.
Raskov H; Orhan A; Gaggar S; Gögenur I
Front Oncol; 2021; 11():668731. PubMed ID: 34094963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
